Prognostic value of upar forms in colon and breast cancer

Informations projet

TIMO PIIRONEN

N° de convention de subvention: QLK4-CT-1999-51464

Projet clôturé

Date de début 1 Août 2000

Date de fin 31 Juillet 2002

Financé au titre de

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coût total € 143 952,00

Contribution de l’UE € 143 952,00

Coordonné par

COPENHAGEN UNIVERSITY HOSPITAL
Denmark

Objectif

Investigation of the clinical prognostic value of soluble urokinase plasminogen activator receptor (uPAR) forms in blood and tissue extracts from patients with colon and breast cancer, aiming to develop new methods which will aid in the decision-making needed in the management of cancer patients.

Champ scientifique

• medical and health sciences › clinical medicine › oncology › breast cancer

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thème(s)

• 1.1.1.-4. - Key action Environment and Health

Appel à propositions

Data not available

Régime de financement

RGI - Research grants (individual fellowships)

Coordinateur

COPENHAGEN UNIVERSITY HOSPITAL

• Contribution de l’UE: Aucune donnée
• Adresse: Stransboulevarden 49 ; 2100 KOEPENHAGEN ; Danemark
• Coût total: Aucune donnée